Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03066011 · ClinicalTrials.gov registry record
Registry of Patients Treated With Systemic Mold-Active Triazoles
A clinical trial, sponsored by Astellas Pharma Global Development.
- Completed
- Registry status
- 2,015
- Enrollment target
NCT03066011 is a clinical trial that has completed, run by Astellas Pharma Global Development. The registered enrollment target is 2,015 participants.
The verdict
NCT03066011 has completed, sponsored by Astellas Pharma Global Development.
- COMPLETED
- Registry status
- 2,015 participants
- Enrollment target
Study Summary
The purpose of this study is to describe representative real-world patterns of care for the management of invasive fungal infections (IFIs), including invasive mold infection (IMI). Specifically, the study goals are to examine real world patient characteristics and treatment patterns, associated healthcare resource utilization, and outcomes associated with use of mold-active triazoles (MATs) to treat invasive fungal infections (IFIs).
Interventions
- DRUG Posaconazole
- DRUG Voriconazole
- DRUG Isavuconazonium sulfate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,015 participants |
| Start Date | 2017-03-16 |
| Est. Completion | 2020-04-24 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03066011
The ClinicalTrials.gov registry entry for NCT03066011 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 2,015 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astellas Pharma Global Development, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Posaconazole is the first listed.
NCT03066011 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03066011 about?
NCT03066011 is a clinical study titled "Registry of Patients Treated With Systemic Mold-Active Triazoles". The purpose of this study is to describe representative real-world patterns of care for the management of invasive fungal infections (IFIs), including invasive mold infection (IMI). Specifically, the study goals are to examine real world patient characteristics and treatment patterns, associated hea...
What is the current status of trial NCT03066011?
This trial is currently completed. The enrollment target is 2,015 participants. The study started on 2017-03-16. Estimated completion is 2020-04-24.
What interventions are being tested in trial NCT03066011?
The interventions under investigation include: Posaconazole (DRUG), Voriconazole (DRUG), Isavuconazonium sulfate (DRUG).
Who is sponsoring clinical trial NCT03066011?
This trial is sponsored by Astellas Pharma Global Development, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.